Showing posts with label Brain tumor. Show all posts
Showing posts with label Brain tumor. Show all posts

Wednesday, November 30, 2022

Tumor-Related Epilepsy and Post-Surgical Outcomes: Tertiary Hospital Experience in Saudi Arabia - Juniper Publishers

 Neurology & Neurosurgery - Juniper Publishers

Abstract

Objectives: Recent studies reported that tumor histopathology plays a significant role in predicting freedom from seizures after epilepsy surgery; however, no consensus among researchers regarding this issue exists. This study retrospectively examined different types of tumor-related epilepsy and post-epilepsy surgical outcomes and the relationship between various tumor Histopathology and these outcomes.

Methods: In this hospital-based retrospective study, patients with brain tumors and drug-resistant epilepsy, which is defined as the failure of two tolerated and appropriately chosen antiepileptic drugs (whether as monotherapies or in combination) to achieve and alleviate sustained seizure freedom, were recruited. These patients underwent a thorough pre-surgical evaluation in an Epilepsy Monitoring Unit (EMU) before deciding to undergo surgical intervention according to an epilepsy case management conference.

Results: One-hundred patients (including 45 children) with brain tumors were included in this study (male: female = 3:2). Most of the patients (93) had G/GNT. No significant differences in outcome were observed among sex, age, or histopathological categories. However, during the first year after epilepsy surgery, most of the low-grade G/GNT cases showed favorable outcomes based on ILAE classes 1 and 2 (61.3% and 9.7%, respectively), whereas high-grade gliomas and meningothelial tumors showed outcomes of ILAE class 1 (40% and 100%, respectively).

Conclusion: Post-epilepsy surgical outcomes of different brain tumors have been achieved with favorable outcomes in children and adults with low-grade gliomas and meningiomas. Thus, pre-surgical evaluation in EMU is highly recommended to enhance better post-epilepsy surgical outcomes.

Keywords: Epilepsy; Brain tumor; Histopathology; Surgery; Saudi Arabia; ILAE

Introduction

Approximately 30%–50% of patients with brain tumors have epilepsy as an initial presentation [1]. However, 6%–45% of patients with brain tumors develop seizures later in life [2,3]. Although the exact mechanism of seizure development in patients with brain tumors is not clearly understood, recent studies have identified that some changes in the peritumoral regions affect the release of neurotransmitters that lead to seizure development [4]. Many studies have reported a relationship between tumor type and seizure frequency. For example, low-grade gliomas and glioneuronal tumors (G/GNT) are associated with a high rate of seizure incidence (85%–92%) [5-7]. In contrast, glioblastomas, which are high-grade tumors, are associated with a low rate of seizure incidence (20%–50%) [8,9]. The incidence rates of seizures in meningiomas, especially in atypical and malignant subtypes, remain understudied [10]. Despite the abundance of knowledge regarding surgical management of resistant forms of epilepsy, including those associated with brain tumors, especially of the low-grade type, prospective studies regarding the medical treatment of epilepsy in this type of patient are scarce [11]. Reportedly, resection of the epileptogenic zone due to the development of brain tumors lead to freedom from or significant control of seizures in 70-90% of patients [12,13]. Furthermore, tumor type, seizure severity, early surgical intervention, frequency during the pre-operative stage, histopathology of the tumors, and the extension of surgical resection to include peritumoral tissues are reportedly the factors that increase the likelihood of freedom from seizures post-operatively [14]. Two of the best predictors of freedom from post-operative seizures include a duration of less than one year since the onset of epilepsy and gross total surgical resection [15,16]. Tumor histopathology plays a significant role in predicting freedom from seizures after epilepsy surgery; however, there is no consensus among researchers regarding this issue [17,18]. This study retrospectively investigated different types of tumor-related epilepsy and their outcomes in the first year after epilepsy surgery.

Materials and Methods

Study design

A hospital-based retrospective study was conducted using secondary data from the epilepsy registry at King Faisal Specialist Hospital and Research Center (KFSH&RC) between 1998 and 2017.

Study population

The included patients underwent surgery for drug-resistant epilepsy. The patients were admitted to the Epilepsy Monitoring Unit (EMU) for long-term monitoring; they underwent presurgical evaluations such as surface electroencephalography (EEG), 3-tesla magnetic resonance imaging (MRI) of the brain, and fluoro-deoxy-glucose positron emission tomography (PET) brain scans. Additionally, a qualified neuropsychologist was present during the evaluation of the enrolled patients with epilepsy. In some patients, intracranial subdural recordings, intracarotid amobarbital procedure (Wada test) and electrocorticography (ECoG), and motor, sensory, and language mapping were performed.

Detailed information about the patients was collected. This information included demographic characteristics (age, gender, handedness, age at onset of the disease) and history and clinical data (type of seizure and frequency, seizure observed at EMU, MRI findings, PET scan, ictal EEG (IEEG) location and type, subdural EEG recording, and inter-ictal EEG [IIEEG] location and type). Moreover, final diagnosis, surgical procedures, and pathology were recorded as the primary outcome. All tumor cases enrolled in this study were reviewed and graded independently by a neuropathologist according to the World Health Organization (WHO) classification [19]. Epilepsy data were discussed in an epilepsy surgery conference with epileptologists, epilepsy surgeons, neuroradiologists, and neuropsychologists to determine the status and surgical candidacy of the patient.

According to the International League Against Epilepsy (ILAE) commission report (1997–2001), six outcomes of interest were proposed [20]. However, the categories 4, 5, and 6 are difficult to measure and implement in daily practice, particularly when parameters related to the quality of life are included. Hence, we suggested simplifying the ILAE classification of epilepsy surgical outcomes with only four categories rather than six to facilitate its application for a new modification that shares the ILAE classification for classes 1, 2, and 3, while classes 4, 5, and 6 would be merged into only one class, called class 4. Thus, the definitions of the classes were divided into four groups:

1. class 1, patients who were completely seizure-free with no auras;

2. class 2, patients with auras but no seizures;

3. class 3, patients experiencing one to three seizure days per year ±auras; and

4. class 4, ranging from four or more seizure days per year to those experiencing ≥ 50% reduction of baseline seizure days ±auras to ≥ 100% increase in baseline seizure days; ±auras. Furthermore, outcomes of classes 1 and 2 were considered favorable, while those of classes 3 and 4 were considered unfavorable. These four outcomes were investigated during the first post-surgical year.

Data analysis

Statistical analysis through cross-tabulation of the tumor groups, pathologies, and progressive outcomes was performed using SAS software (ver. 9.4). Due to the small sample size, some subgroups, pathologies, and outcomes were collapsed. Proportional statistics, and chi-square and Fisher’s exact test were used to explain the findings within a 95% confidence interval (CI). A P-value of < 0.05 was considered statistically significant.

Results

Among the 100 patients with brain tumors related epilepsy included in this study, 59 (59%) were males, and 41 (41%) were females. The incidence of brain tumor-related epilepsy (BTRE) in our center was lower among children than adults (45% versus 55%). However, the differences among sex, age, and the histopathology categories were not statistically significant (P = 0.111 and 0.878, respectively) as depicted in Table 1.

According to histopathological findings, the cases of brain tumors were grouped into three main categories (Table 2). Most of the tumors (93%) were low-grade gliomas or glioneuronal tumors (G/GNT) followed by high-grade gliomas (5%); only two meningioma cases (2%) were detected. Among the three main categories of brain tumors, low-grade G/GNT consisted of 11 entities. Under this category, 40 tumors were gangliogliomas, and 29 tumors were Dysembryoplastic neuroepithelial tumors (DNET). Among the five high-grade gliomas, three were astrocytic tumors. Interestingly, only two meningiomas were found. Table 2 details the pathological categories.

In this study, the primary postoperative outcome was evaluated using the modified ILAE classification described in the methodology section. During the first post-surgical year, most patients with low-grade G/GNT experienced favorable outcomes (classes 1 and 2, 61.3% and 9.7%, respectively) as shown in Table 3. In contrast, approximately 40% of the patients with high-grade gliomas showed favorable outcomes (ILAE class 1). Both meningioma cases (100%) showed outcomes of ILAE class 1. Among the 100 patients with brain tumors, 71 (71%) patients, including 66 patients with low-grade G/GNT, three patients with high-grade gliomas, and two patients with meningiomas, experienced favorable outcomes during the one-year post-surgical period (Table 4). Moreover, the incidence of favorable outcome was higher in adult patients than in children (52.2% versus 47.8%) and in male versus female patients (41% versus 30%). However, these differences in outcome dependent on histopathological type, age, and sex were not statistically significant (P = 0.864, 0.559, and 0.159, respectively).

Discussion

From the epilepsy registry at KFSH&RC, 100 patients who underwent surgery for tumor-related epilepsy were included in this study. Varying associations between different brain tumor types and epilepsy have been reported. Most studies show gangliogliomas to be the most common tumor type associated with epilepsy, followed by DNET, oligodendrogliomas, and astrocytomas [21-24]. These findings support our results, that is, most of our patients had low-grade G/GNT (93.0%), most of which were gangliogliomas (40%) followed by DNET (29%). Furthermore, Babini et al. reported that gangliogliomas (66.7% versus 40%) [25] were the most frequent tumors among their patients; however, their sample size was smaller (30 cases) than in our study. Contrary to our findings, Kahlenberg et al. reported that mixed oligo-astrocytomas were the most prevalent tumors followed by astrocytomas grade II and oligodendrogliomas of grade II [25]. The incidence of high-grade gliomas was lower (5%) in our study than in a study by Michelucci et al. in Italy (77.0%), a finding attributed to a significantly high prevalence of high-grade gliomas in that area [15].

Seizures have a great impact on patient and caregiver quality of life. Seizures affect all aspects of a patient’s life, such as employment, social life, driving, and entertainment. Epilepsy surgery as described in many recent studies, is considered to relieve tumor-related epilepsy and achieve favorable outcomes [15,26,27]. However, in some cases, epilepsy persist even after resecting the primary focus [25]. All of our patients underwent well-planned epilepsy surgery, which is defined as the resection of the tumor and peritumoral tissues [23]. Consequently, our patients showed varying degrees of improvement during the first post-surgical year depending on the type of brain tumor (low-grade G/GNT versus high-grade gliomas); however, the differences were not statistically significant (P = 0.864). For example, patients with low-grade tumors, which were the most common type of tumor in our study (93 cases), showed a favorable outcome during the first post-epilepsy surgery year with approximately 71% freedom from seizure (classes 1 and 2). Michelucci et al. reported findings that were similar to our study, that is, better outcomes was observed in patients with low-grade gliomas (76%) [15]. In contrast, Kahlenberg et al. showed that about half of their patients (30 out of 54; 55.6%) with brain tumor-related epilepsy showed good post-surgical outcomes (seizure-free periods > 12 months) [25]. These proportions were lower than those observed in our study (55.6% versus 71%).

In our opinion, the ILAE classification of epilepsy surgical outcomes should be simplified using only four categories rather than six to facilitate ILAE application. Hence, whenever patients have four or more seizures (outcomes 4, 5, and 6), they should be classified into one category (category 4). The currently used ILAE Commission on Neurosurgery in 2001[28] still has some elements that make the use of categories 4, 5, and 6 difficult to measure and implement in daily practice, particularly when including parameters related to quality of life. This new modified classification can help the researchers in their ongoing studies.

Furthermore, few patients in our study had high-grade gliomas (five) or meningiomas (two). These patients showed a favorable outcome during the first post-surgical year (60% and 100%, respectively). Michelucci et al. reported similar results in which 58% of their patients with high-grade glioma became seizure free after tumor removal [15].

Pediatric and adult groups showed no significant differences regarding seizure outcomes during the first post-surgical year (P = 0.559); thus, we cannot claim that surgery is more beneficial in pediatric patients. These findings were similar to those of other studies [23].

Our study has three main limitations:

1. the sample size was small and included only five patients with high-grade gliomas and two patients with meningothelial tumors (two cases); this made comparison with low-grade G/GNT insufficient although our sample size (100 cases) is comparable to that of other studies;

2. this series of tumor-related epilepsy does not represent the population with epilepsy in Saudi Arabia because not all patients with tumor-related epilepsy are eligible to be admitted to our institution, and thus, they are treated; and

3. the possibility of bias occurring during data collection in a retrospective study. Despite the above-mentioned limitations, we hope that our study provides valuable information on one of the most debatable topics in epilepsy surgery in the country and throughout the Middle East.

Conclusion

In this study, the most common tumor-related epilepsy was low-grade G/GNT. Outcomes of post epilepsy surgery of different brain tumors have been achieved with a favorable outcome in both children and adults. Thus, thorough pre-surgical evaluation of patients with brain tumor-related epilepsy in EMU is highly recommended to enhance better post-epilepsy surgical outcomes. Further prospective, multicenter studies are needed with a larger number of patients to allow the findings to be more generalizable in Saudi Arabia.

Click here: https://juniperpublishers.com/index.php 

Friday, November 20, 2020

Melatonin Inhibitory Effects on Forming Brain Tumor - Juniper Publishers

 Endocrinology and Thyroid Research - Juniper Publishers


Abstract

Melatonin is a neurohormone secreted by the pineal and extra pineal organs with oncostatic and tumor inhibitory effects. There is considerable evidence that melatonin may be of use in the prevention and treatment of cancer. This manuscript will review some of the underlying molecular mechanisms by melatonin’s antitumor properties with emphasizing on the formation of brain tumors.

Keywords: Melatonin; Brain tumor; Glioblastoma stem-like cell

Introduction

Central nervous system tumors contain many separate types of tumors in the brain parenchyma, meninges, and spinal cord. They can be divided into primary or secondary/metastatic tumors, benign or malignant tumors, based on the WHO classification with varying prevalence and assigned into four grades, from a very benign tumor to highly malignant tumors (Grade I to IV). Gliomas (intra-axial tumors inside brain/spinal cord parenchyma) are the most common malignant types with 75% prevalence than astrocytomas, oligodendrogliomas, mixed oligoastrocytomas, medulloblastomas (MBs), midline diffuse astrocytoma, diffuse intrinsic pontine gliomas (DIPG) and hemangioblastomas (HMBs) [1,2]

Melatonin is L-tryptophan derivatives neurohormones secreted predominantly in the brain (cerebellum and cerebral cortex, raphe nuclei, striate body), spinal cord, retina, lens, cochlea, skin, gastrointestinal tracts such as the stomach, small and intestine, lymphocytes, bones, murine bone marrow, platelets, testes, and ovaries. In the neuro-endocrinal system, melatonin has a crucial role in energy metabolism and its secretion is stimulated by darkness and decreased by light, serum levels peaking between 2 a.m. and 5 a.m. Also, it has some other functions such as synthesis, distribution and divers’ action of different receptors in the specific area of the brain, cellular signaling, and messenger system. Rise melatonin levels in the blood during the night could send signals to the body’s cells and organs into appropriate homeostatic metabolic rhythms. Therefore, melatonin secretion disruption can lead to the progression of target organs cancer [3-5]. This mini review highlights the underlying mechanism by melatonin’s antitumor properties with emphasizing on the formation of brain tumor.

Melatonin and Tumor Growth Inhibition

Melatonin acts as a hormone and based on accumulating data in the last decade also as a cell protector, involved in immunomodulation, antioxidative processes, and hematopoiesis [5]. Several experimental studies have highlighted that melatonin has neuroprotective benefits when given as either a prophylactic or curative treatment in several animal models of brain damage [6]. In 2019, Maitra and et al revealed that melatonin deficiency not only can have a debilitating effect on normal physiology, also can create some abnormal conditions such as malignancy in the brain and finally can lead to glioma. Hence, it can account for high expectations to be included as an adjuvant in cancer treatments [3,7,8].

In 2013, QU and et al with the hypothesis that melatonin may have an inhibiting role in the apoptotic pathway and beneficial efficacy in the prevention of cancer, have investigated the different concentrations of melatonin on C6 glioma cell. They opt them because these cell lines are susceptible to expressing MT1 and MT2 receptors of melatonin, therefore they can be modulated by melatonin at a pharmacological concentration to the treatment of glioma. They also transcriptional regulation of three involved genes (Nestin, Bmi-1, and Sox2) in developing the nervous system as differentiation and proliferation markers in neural cells. In this study melatonin with 3 mM concentration increase the mRNA levels of Nestin, Bmi-1, and Sox2 in a similar pattern, with the highest mRNA levels. At 5 mM concentrations of melatonin, the mRNA levels of Nestin, Bmi-1, and Sox2 were reduced and were correlated with changes ocurred in survival assays [7]. The new therapeutic strategies of brain tumors focusing on glioblastoma with a subpopulation of stem-like cells responsible for glioma proliferation, therapeutic resistance, and tumor recurrence [4,9].

Notably, glioblastoma stem-like cells (GSCs), as protagonists in glioma growth scenarios, can increase tumor-initiating capacity. The results of a research conducted by Chen and et al in 2016, on the effects of melatonin in GSC biology, represent the high capability of melatonin in suppressing self-renewal properties of GSCs. A possible explanation of the anti-oncogenic role of melatonin might be that, it can mediate silencing of transcription factor STAT3 signaling through direct EZH2–STAT3 interaction and contributes to the transcriptional inactivation of H3K27me3 through EZH2 S21 dephosphorylation in GSCs [9]. GSCs and confirmed their claim through Neurosphere-forming assay. The storyline related by this scenario was the reduction in the expression levels of EZH2 and following that they found more strikingly NOTCH1 as a downstream target of EZH2 and core molecule in transfer EZH2-mediated signals which coincidentally has been reduced by melatonin in the GSCs [10,11].

Conclusion

This manuscript investigated some instances of the beneficial outcomes in reducing malignant brain tumor formation by melatonin. Moreover, there is a lack of studies focusing on precise molecular mechanisms by melatonin in different types of brain tumors. Subsequently, more in-depth studies are needed to find therapeutic and preventive strategies through the use of melatonin for all types of brain tumors. Because not only melatonin has extraordinary properties in human physiology, it also is chemically synthesized and available for further investigations.

Parking Demand for Elementary & Secondary Schools in Jordan- Juniper Publishers

  Civil Engineering- Juniper Publishers Abstract This study aimed at investigating parking demand at elementary and secondary schools in Irb...